LB Pharmaceuticals, Inc. (LBRX)
NASDAQ:LBRX
Want to see LBRX full AI Analyst Report?
LBRX Stock Chart & Stats
$30.52
--
Market closed
$30.52
--
Day’s Range― - ―
52-Week Range$13.36 - $33.47
Previous CloseN/A
VolumeN/A
Average Volume (3M)239.05K
Market Cap
$814.99M
Enterprise Value$484.88M
Total Cash (Recent Filing)$365.64M
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta1.39
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,676,653
10 Day Avg. Volume318,803
30 Day Avg. Volume239,047
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-15.97
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.91K
Enterprise Value/Ebitda-12.42
Forecast
1Y Price Target
$46.83Price Target Upside53.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened 2025 Balance SheetA materially positive equity base and very low debt in 2025 provide durable financial flexibility for a clinical-stage biotech. This reduces near-term solvency risk, supports continued R&D spend and partnership negotiations, and lengthens runway versus pre-2025 capital constraints.
Advancing Multi-year Clinical PipelineA clear multi-year development calendar for LB-102 aligns program milestones across indications, creating multiple structural value inflection points. Coupled with a recent financing, this supports sustained R&D execution, potential partnering/licensing opportunities, and de-risks near-term program continuity.
Board And Leadership StrengtheningBringing experienced neuroscience R&D leadership and consolidating operational/commercial responsibilities improves governance and execution capacity. This structural upgrade enhances trial oversight, regulatory interaction capability, and readiness for later-stage development and potential commercialization.
Bears Say
No Revenue GenerationPersistent absence of product revenue means the company remains dependent on financing to fund operations indefinitely until commercialization. This structural shortfall limits self-sustaining cash flows, raises execution risk for trials and commercialization, and increases future dilution probability.
Sustained Operating Cash BurnChronic negative operating and free cash flows create ongoing funding needs and dependency on external capital. Even with 2025 improvement, sustained burn pressures planning, may force dilutive financings or limit R&D breadth if capital markets tighten, impacting long-term program continuity.
Historical Balance-sheet Stress And Capital RelianceA history of negative equity signals prior solvency strain and an established pattern of raising capital to operate. That structural reliance increases the probability of future dilution, complicates long-term investor returns and could constrain strategic choices if further financing is needed.
LB Pharmaceuticals, Inc. News
LBRX FAQ
What was LB Pharmaceuticals, Inc.’s price range in the past 12 months?
LB Pharmaceuticals, Inc. lowest stock price was $13.36 and its highest was $33.47 in the past 12 months.
What is LB Pharmaceuticals, Inc.’s market cap?
LB Pharmaceuticals, Inc.’s market cap is $814.99M.
When is LB Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were LB Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is LB Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts LB Pharmaceuticals, Inc.’s price is currently Undervalued.
Does LB Pharmaceuticals, Inc. pay dividends?
LB Pharmaceuticals, Inc. does not currently pay dividends.
What is LB Pharmaceuticals, Inc.’s EPS estimate?
LB Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LB Pharmaceuticals, Inc. have?
LB Pharmaceuticals, Inc. has 28,676,653 shares outstanding.
What happened to LB Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LB Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in LBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LB Pharmaceuticals, Inc. Stock Smart Score
Company Description
LB Pharmaceuticals, Inc.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
LBRX Stock 12 Month Forecast
Average Price Target
$46.83
▲(53.45% Upside)
Technical Analysis
Ownership Overview
24.62% Insiders
13.02% Mutual Funds
9.05% Other Institutional Investors
45.97% Public Companies and
Individual Investors